MedPath

AL-78898A

Generic Name
AL-78898A

A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)

Phase 2
Terminated
Conditions
Geographic Atrophy
Interventions
Drug: Sham injection
First Posted Date
2012-05-22
Last Posted Date
2014-01-20
Lead Sponsor
Alcon Research
Target Recruit Count
10
Registration Number
NCT01603043

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

Phase 2
Completed
Conditions
Exudative Age-Related Macular Degeneration
Interventions
First Posted Date
2010-07-05
Last Posted Date
2013-06-04
Lead Sponsor
Alcon Research
Target Recruit Count
99
Registration Number
NCT01157065
Locations
🇺🇸

Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

Phase 1
Completed
Conditions
Age-Related Macular Degeneration
First Posted Date
2007-05-16
Last Posted Date
2010-03-18
Lead Sponsor
Potentia Pharmaceuticals, Inc.
Target Recruit Count
27
Registration Number
NCT00473928
Locations
🇺🇸

United States, Minnesota, Rochester, Minnesota, United States

🇺🇸

United States, Florida, Miami, Florida, United States

🇺🇸

United States, New Hampshire, Portsmouth, New Hampshire, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath